# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
- SEC Filing
In the near term, Lyra Therapeutics will focus on the two ongoing ENLIGHTEN Phase 3 trials evaluating LYR-210, a bioabsorbable ...
HC Wainwright & Co. analyst Matthew Caufield downgrades Lyra Therapeutics (NASDAQ:LYRA) from Buy to Neutral and announce...
Jefferies analyst Dennis Ding downgrades Lyra Therapeutics (NASDAQ:LYRA) from Buy to Hold and lowers the price target from $...